对肺部出血的雾化松酸的研究取得了进展
Ping Zhang1, Jiaoni Zheng1, Xuefeng Shan1
1Department of Pharmacy, Bishan Hospital of Chongqing Medical University, Chongqing, China.
European journal of clinical pharmacology
|November 29, 2024
概括
雾化松酸 (TXA) 有效地治疗肺出血,副作用最小. 这种吸入式抗纤维解药可提供局部血静,有望为全身治疗提供更安全的替代方案.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 关键的护理关键的护理
背景情况:
- 肺出血是一种危急的疾病,由于肺组织出血,导致严重的呼吸困扰.
- 雾化松酸 (TXA) 由于其局部静血作用和降低系统风险,具有潜在的治疗作用.
研究的目的:
- 审查目前关于雾化TXA治疗肺出血的疗效和安全性的研究.
主要方法:
- 在PubMed,Embase和Scopus数据库中进行了系统的文献搜索,直到2023年11月.
- 关键词包括"血","肺出血","特兰胺酸"和"雾化".
- 研究选择侧重于肺出血中雾化TXA的使用,分析来自RCT,病例系列和病例报告的数据.
主要成果:
- 典型的剂量是500毫克/5毫升的雾化TXA,每天服用3-4次.
- 雾化TXA证明有效控制出血,与全身药物相比,但静脉血栓形成的风险较低.
- 治疗一般耐受良好,罕见的局部反应如支气管,由支气管扩展剂管理.
结论:
- 雾化TXA是一种创新的,微创的选择,用于肺出血,具有良好的安全性.
- 需要进一步的大规模,高质量的研究,以建立标准化治疗指南.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
623
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
623
Epistaxis
134
Epistaxis, or nosebleeds, occurs when small, swollen blood vessels in the nasal mucous membrane rupture. Typically, the anterior septum is the primary site of occurrence.
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
134
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
150
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
150


